Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 06 2021
Historique:
received: 04 12 2020
accepted: 10 05 2021
entrez: 8 6 2021
pubmed: 9 6 2021
medline: 29 6 2021
Statut: epublish

Résumé

In routine diagnostic pathology, cancer biopsies are preserved by formalin-fixed, paraffin-embedding (FFPE) procedures for examination of (intra-) cellular morphology. Such procedures inadvertently induce DNA fragmentation, which compromises sequencing-based analyses of chromosomal rearrangements. Yet, rearrangements drive many types of hematolymphoid malignancies and solid tumors, and their manifestation is instructive for diagnosis, prognosis, and treatment. Here, we present FFPE-targeted locus capture (FFPE-TLC) for targeted sequencing of proximity-ligation products formed in FFPE tissue blocks, and PLIER, a computational framework that allows automated identification and characterization of rearrangements involving selected, clinically relevant, loci. FFPE-TLC, blindly applied to 149 lymphoma and control FFPE samples, identifies the known and previously uncharacterized rearrangement partners. It outperforms fluorescence in situ hybridization (FISH) in sensitivity and specificity, and shows clear advantages over standard capture-NGS methods, finding rearrangements involving repetitive sequences which they typically miss. FFPE-TLC is therefore a powerful clinical diagnostics tool for accurate targeted rearrangement detection in FFPE specimens.

Identifiants

pubmed: 34099699
doi: 10.1038/s41467-021-23695-8
pii: 10.1038/s41467-021-23695-8
pmc: PMC8184748
doi:

Substances chimiques

BCL6 protein, human 0
Proto-Oncogene Proteins c-bcl-6 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3361

Références

Genome Biol. 2020 Mar 23;21(1):73
pubmed: 32293513
Mod Pathol. 2019 May;32(5):609-620
pubmed: 30459475
Nucleic Acids Res. 2018 Sep 6;46(15):e91
pubmed: 29800273
Cancer Sci. 2014 Apr;105(4):437-44
pubmed: 24450488
J Clin Oncol. 2019 Dec 10;37(35):3359-3368
pubmed: 31498031
Lung Cancer. 2020 Feb;140:46-54
pubmed: 31862577
Blood. 2015 Nov 26;126(22):2466-74
pubmed: 26373676
Nat Methods. 2009 Nov;6(11):837-42
pubmed: 19820713
Nat Commun. 2018 Nov 29;9(1):4938
pubmed: 30498195
Nature. 2007 Aug 23;448(7156):959-63
pubmed: 17713539
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22
pubmed: 31738428
Blood. 2018 May 3;131(18):2060-2064
pubmed: 29475959
Am J Clin Pathol. 2020 Feb 8;153(3):353-359
pubmed: 31872861
Mol Cell Oncol. 2014 Jul;1(1):
pubmed: 26203462
Science. 2002 Feb 15;295(5558):1306-11
pubmed: 11847345
Nat Biotechnol. 2014 Oct;32(10):1019-25
pubmed: 25129690
EBioMedicine. 2016 Dec;14:55-64
pubmed: 27916548
J Mol Diagn. 2019 May;21(3):375-383
pubmed: 30605765
Cancer Med. 2019 Dec;8(18):7556-7566
pubmed: 31651105
Nat Methods. 2012 Oct;9(10):969-72
pubmed: 22961246
Hematol Oncol. 2020 Apr;38(2):171-180
pubmed: 31955451
Methods. 2020 Jan 1;170:17-32
pubmed: 31351925
Nature. 2020 Feb;578(7793):112-121
pubmed: 32025012
Nat Genet. 2018 Oct;50(10):1388-1398
pubmed: 30202056
Trends Genet. 2016 Sep;32(9):530-542
pubmed: 27478068
Hum Mol Genet. 1992 Nov;1(8):625-32
pubmed: 1301171
Bioinformatics. 2018 Jan 15;34(2):338-345
pubmed: 29048467
Mod Pathol. 2020 Jul;33(7):1350-1359
pubmed: 32047232
Epigenetics Chromatin. 2014 Jun 16;7:10
pubmed: 25031611
Blood. 2019 Jan 24;133(4):377-380
pubmed: 30510084
Blood Adv. 2018 Oct 23;2(20):2755-2765
pubmed: 30348671
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Genome Biol. 2017 Jun 27;18(1):125
pubmed: 28655341
Blood. 2003 Aug 15;102(4):1443-8
pubmed: 12738680
Histopathology. 2013 Sep;63(3):418-24
pubmed: 23795946
Genome Res. 2011 Apr;21(4):505-14
pubmed: 21393386
Genes Chromosomes Cancer. 2012 Apr;51(4):338-43
pubmed: 22420028
Leuk Lymphoma. 2017 May;58(5):1037-1051
pubmed: 27678023

Auteurs

Amin Allahyar (A)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.

Mark Pieterse (M)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.

Joost Swennenhuis (J)

Cergentis BV, Utrecht, the Netherlands.

G Tjitske Los-de Vries (GT)

Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Pathology and Cancer Center Amsterdam, Amsterdam, the Netherlands.

Mehmet Yilmaz (M)

Cergentis BV, Utrecht, the Netherlands.

Roos Leguit (R)

University Medical Centre Utrecht, Department of Pathology, Utrecht, the Netherlands.

Ruud W J Meijers (RWJ)

University Medical Centre Utrecht, Department of Pathology, Utrecht, the Netherlands.

Robert van der Geize (R)

Laboratorium Pathologie Oost-Nederland, Hengelo, the Netherlands.

Joost Vermaat (J)

Leiden University Medical Centre, Department of Hematology, Leiden, the Netherlands.

Arjen Cleven (A)

Leiden University Medical Center, Department of Pathology, Leiden, the Netherlands.

Tom van Wezel (T)

Leiden University Medical Center, Department of Pathology, Leiden, the Netherlands.

Arjan Diepstra (A)

University of Groningen, University Medical Centre Groningen, Department of Pathology & Medical Biology, Groningen, the Netherlands.

Léon C van Kempen (LC)

University of Groningen, University Medical Centre Groningen, Department of Pathology & Medical Biology, Groningen, the Netherlands.

Nathalie J Hijmering (NJ)

Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Pathology and Cancer Center Amsterdam, Amsterdam, the Netherlands.

Phylicia Stathi (P)

Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Pathology and Cancer Center Amsterdam, Amsterdam, the Netherlands.

Milan Sharma (M)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.

Adrien S J Melquiond (ASJ)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.

Paula J P de Vree (PJP)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.

Marjon J A M Verstegen (MJAM)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.

Peter H L Krijger (PHL)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.

Karima Hajo (K)

Cergentis BV, Utrecht, the Netherlands.

Marieke Simonis (M)

Cergentis BV, Utrecht, the Netherlands.

Agata Rakszewska (A)

Cergentis BV, Utrecht, the Netherlands.

Max van Min (M)

Cergentis BV, Utrecht, the Netherlands.

Daphne de Jong (D)

Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Pathology and Cancer Center Amsterdam, Amsterdam, the Netherlands.

Bauke Ylstra (B)

Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Pathology and Cancer Center Amsterdam, Amsterdam, the Netherlands.

Harma Feitsma (H)

Cergentis BV, Utrecht, the Netherlands.

Erik Splinter (E)

Cergentis BV, Utrecht, the Netherlands. erik.splinter@cergentis.com.

Wouter de Laat (W)

Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands. w.laat@hubrecht.eu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH